Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.39 |
| ▸ | SUV39H2 | Q9H5I1 | 2/20 | 0.39 |
| ▸ | PRKCI | P41743 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14403246 | 0.87 | TBK1 (0.43) | TBK1IKBKESUV39H2 | |
| SCHEMBL1724962 | 0.83 | ALDH1A1 (0.40) | TBK1IKBKESUV39H2LMNAMAPT | |
| SCHEMBL12208682 | 0.82 | IKBKE (0.41) | TBK1IKBKESUV39H2LMNAMAPT | |
| SCHEMBL633835 | 0.81 | TBK1 (0.38) | TBK1IKBKESUV39H2 | |
| SCHEMBL21213955 | 0.81 | SUV39H2 (0.41) | TBK1IKBKESUV39H2 | |
| SCHEMBL14117573 | 0.79 | TBK1 (0.39) | TBK1IKBKESUV39H2LMNAMAPT | |
| SCHEMBL13832397 | 0.79 | SUV39H2 (0.41) | TBK1IKBKESUV39H2LMNAMAPT | |
| SCHEMBL745424 | 0.79 | TBK1 (0.39) | TBK1IKBKESUV39H2LMNAMEN1 | |
| SCHEMBL2384758 | 0.79 | HTR2C (0.40) | TBK1IKBKESUV39H2SMN1; SMN2HPGD | |
| SCHEMBL22816649 | 0.79 | IKBKE (0.38) | TBK1IKBKESUV39H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3526196-B1 | ARYL AND HETEROARYL ETHER DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS | MERCK SHARP & DOHME LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4363425-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-06-08 | — | — | US | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| WO-2010121011-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-10-21 | — | — | WO | disclosed |
| US-7605289-B2 | Benzamide derivatives and uses related thereto | AMGEN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-7605289-B2 | Benzamide derivatives and uses related thereto | AMGEN, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| EP-0207500-B1 | ISOQUINOLINE DERIVATIVES | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-11-13 | — | — | EP | disclosed |
| EP-0281661-B1 | 2-ALKOXYCARBONYL-4-(4-PYRIDYL)CYCLOHEXANONES AND PROCESS FOR PREPARING THEM | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4845228-A | INTERMEDIATES FOR CARDIOTONIC AGENTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-07-04 | — | — | US | disclosed |
| US-4824952-A | CARDIOTONIC AGENTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1989-04-25 | — | — | US | disclosed |
| US-4639521-A | CARDIOTONIC AGENTS | MITSUI TOATSU CHEMICALS, INC. (JP) | 1987-01-27 | — | — | US | disclosed |
| EP-0207500-A2 | Isoquinoline derivatives | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1987-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | TBK1 2121/4885IKBKE 3159/4885SUV39H2 107/4885 |
| US-20230173078-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | TBK1 2121/4885IKBKE 3159/4885SUV39H2 107/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | TBK1 1516/4885IKBKE 1359/4885SUV39H2 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.